Civica Takes First Foray Into Biosimilars With GeneSys Insulins Partnership
Initiative Will Produce Biosimilars Of Lantus, Humalog And Novolog
Executive Summary
Non-profit generics firm Civica is partnering with GeneSys Biologics to make affordable biosimilars of Lantus, Humalog and Novolog for the US market, which it aims to sell at $30 a vial or $55 per pack of cartridges.
You may also be interested in...
Civica Adds New Partners To Access Initiatives
Civica has selected Profil as its clinical partner as it develops its affordable range of biosimilar insulins, and has also added pharmacy benefit manager EmsanaRx to its generic CivicaScript network.
Civica Rx COO McCoy To Step Into CEO Role From 1 June
Civica Rx’s chief operating officer Ned McCoy is to step up as CEO, ahead of the company’s landmark manufacturing facility commencing operations in early 2024.
Generics Bulletin Editor’s Picks For Q1 2022
Looking back over the first quarter of 2022, Generics Bulletin executive editor David Wallace picks out highlights from January to March that include a number of major deals in the biosimilars sector, warnings of increasing price pressure on generics, and key strategy updates from companies across the off-patent sector.